Management of pulmonary hypertension due to heart failure with preserved ejection fraction

Manreet Kanwar, Ryan J. Tedford, Richa Agarwal, Megan M. Clarke, Claire Walter, George Sokos, Srinivas Murali, Raymond L. Benza

Research output: Contribution to journalArticle

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a major cause of HF-related morbidity and mortality, with no medical therapy proven to modify the underlying disease process and result in improvements in survival. With long-standing pulmonary venous congestion, a majority of HFpEF patients develop pulmonary hypertension (PH). Elevated pulmonary pressures have been shown to be a major determinant of mortality in this population. Given the paucity of available disease-modifying therapies for HFpEF, there has been a considerable interest in evaluating new therapeutic options specifically targeting PH in this patient population.

Original languageEnglish (US)
Pages (from-to)501
Number of pages1
JournalCurrent Hypertension Reports
Volume16
Issue number12
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Pulmonary Hypertension
Heart Failure
Lung
Mortality
Hyperemia
Population
Therapeutics
Morbidity
Pressure
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kanwar, M., Tedford, R. J., Agarwal, R., Clarke, M. M., Walter, C., Sokos, G., ... Benza, R. L. (2014). Management of pulmonary hypertension due to heart failure with preserved ejection fraction. Current Hypertension Reports, 16(12), 501. https://doi.org/10.1007/s11906-014-0501-5

Management of pulmonary hypertension due to heart failure with preserved ejection fraction. / Kanwar, Manreet; Tedford, Ryan J.; Agarwal, Richa; Clarke, Megan M.; Walter, Claire; Sokos, George; Murali, Srinivas; Benza, Raymond L.

In: Current Hypertension Reports, Vol. 16, No. 12, 01.12.2014, p. 501.

Research output: Contribution to journalArticle

Kanwar, M, Tedford, RJ, Agarwal, R, Clarke, MM, Walter, C, Sokos, G, Murali, S & Benza, RL 2014, 'Management of pulmonary hypertension due to heart failure with preserved ejection fraction', Current Hypertension Reports, vol. 16, no. 12, pp. 501. https://doi.org/10.1007/s11906-014-0501-5
Kanwar, Manreet ; Tedford, Ryan J. ; Agarwal, Richa ; Clarke, Megan M. ; Walter, Claire ; Sokos, George ; Murali, Srinivas ; Benza, Raymond L. / Management of pulmonary hypertension due to heart failure with preserved ejection fraction. In: Current Hypertension Reports. 2014 ; Vol. 16, No. 12. pp. 501.
@article{87de39525a3e46a8a74400b3d1d9b8f9,
title = "Management of pulmonary hypertension due to heart failure with preserved ejection fraction",
abstract = "Heart failure with preserved ejection fraction (HFpEF) is a major cause of HF-related morbidity and mortality, with no medical therapy proven to modify the underlying disease process and result in improvements in survival. With long-standing pulmonary venous congestion, a majority of HFpEF patients develop pulmonary hypertension (PH). Elevated pulmonary pressures have been shown to be a major determinant of mortality in this population. Given the paucity of available disease-modifying therapies for HFpEF, there has been a considerable interest in evaluating new therapeutic options specifically targeting PH in this patient population.",
author = "Manreet Kanwar and Tedford, {Ryan J.} and Richa Agarwal and Clarke, {Megan M.} and Claire Walter and George Sokos and Srinivas Murali and Benza, {Raymond L.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1007/s11906-014-0501-5",
language = "English (US)",
volume = "16",
pages = "501",
journal = "Current Hypertension Reports",
issn = "1522-6417",
publisher = "Current Medicine Group",
number = "12",

}

TY - JOUR

T1 - Management of pulmonary hypertension due to heart failure with preserved ejection fraction

AU - Kanwar, Manreet

AU - Tedford, Ryan J.

AU - Agarwal, Richa

AU - Clarke, Megan M.

AU - Walter, Claire

AU - Sokos, George

AU - Murali, Srinivas

AU - Benza, Raymond L.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Heart failure with preserved ejection fraction (HFpEF) is a major cause of HF-related morbidity and mortality, with no medical therapy proven to modify the underlying disease process and result in improvements in survival. With long-standing pulmonary venous congestion, a majority of HFpEF patients develop pulmonary hypertension (PH). Elevated pulmonary pressures have been shown to be a major determinant of mortality in this population. Given the paucity of available disease-modifying therapies for HFpEF, there has been a considerable interest in evaluating new therapeutic options specifically targeting PH in this patient population.

AB - Heart failure with preserved ejection fraction (HFpEF) is a major cause of HF-related morbidity and mortality, with no medical therapy proven to modify the underlying disease process and result in improvements in survival. With long-standing pulmonary venous congestion, a majority of HFpEF patients develop pulmonary hypertension (PH). Elevated pulmonary pressures have been shown to be a major determinant of mortality in this population. Given the paucity of available disease-modifying therapies for HFpEF, there has been a considerable interest in evaluating new therapeutic options specifically targeting PH in this patient population.

UR - http://www.scopus.com/inward/record.url?scp=84939426423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939426423&partnerID=8YFLogxK

U2 - 10.1007/s11906-014-0501-5

DO - 10.1007/s11906-014-0501-5

M3 - Article

VL - 16

SP - 501

JO - Current Hypertension Reports

JF - Current Hypertension Reports

SN - 1522-6417

IS - 12

ER -